XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF (LOSS) INCOME - USD ($)
shares in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenues [Abstract]        
Product sales $ 0 $ 0 $ 0 $ 22,334,000
Operating expenses:        
Cost of products 0 0 0 5,742,000
Research and development expenses 4,380,000 5,569,000 14,994,000 15,156,000
Selling, general and administrative expenses 21,283,000 8,423,000 47,469,000 23,431,000
Intangible asset amortization 0 0 0 406,000
Changes in fair value of contingent consideration 0 (69,000) 0 3,327,000
Gain on sale of Hospital Products 0 0 0 (45,760,000)
Restructuring income 0 (226,000) (53,000) (43,000)
Total operating expense 25,663,000 13,697,000 62,410,000 2,259,000
Operating (loss) income (25,663,000) (13,697,000) (62,410,000) 20,075,000
Investment and other income (expense), net 489,000 213,000 1,531,000 (906,000)
Interest expense (1,929,000) (3,259,000) (5,788,000) (9,686,000)
Gain from release of certain liabilities 0 0 166,000 0
Other expense - changes in fair value of contingent consideration payable 0 0 0 (435,000)
(Loss) income before income taxes (27,103,000) (16,743,000) (66,501,000) 9,048,000
Income tax benefit (5,101,000) (5,040,000) (11,473,000) (9,258,000)
Net (loss) income $ (22,002,000) $ (11,703,000) $ (55,028,000) $ 18,306,000
Net loss per share - basic (in dollars per share) $ (0.38) $ (0.20) $ (0.94) $ 0.36
Net loss per share - diluted (in dollars per share) $ (0.38) $ (0.20) $ (0.94) $ 0.35
Weighted average number of shares outstanding - basic (in shares) 58,585 58,213 58,506 51,206
Weighted average number of shares outstanding - diluted (in shares) 58,585 58,213 58,506 52,849